By Stephen Nakrosis


AbbVie Inc. on Tuesday said the U.S. Food and Drug Administration approved Qulipta for the preventive treatment of episodic migraine in adults.

The company said Qulipta, or atogepant, "demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo."

Michael Severino, vice chairman and president of AbbVie, said "Millions of people living with migraine often lose days of productivity each month because attacks can be debilitating. Qulipta can help by reducing monthly migraine days with a once-daily, oral dose that works quickly and continuously."

AbbVie said it is the only pharmaceutical company offering three treatments across the full spectrum of migraine.


Write to Stephen Nakrosis at


(END) Dow Jones Newswires

September 28, 2021 19:15 ET (23:15 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more AbbVie Charts.
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more AbbVie Charts.